Clinicopathological Roles of Aberrantly Expressed Recoverin in Malignant Tumor Cells
Clinicopathological Roles of Aberrantly Expressed Recoverin in Malignant Tumor Cells
复制标题
DOI：
10.1159/000253486
复制
发表时间：
2010-01-01
影响因子：
2.1
通讯作者：
Nakazawa, Mitsuru
中科院分区：
文献类型：
--
作者：
Matsuo, Sachiyo;Ohguro, Hiroshi;Nakazawa, Mitsuru
目的：癌症相关性视网膜病变(CAR)是一种副肿瘤综合征的眼部表现，在肿瘤细胞中对视网膜特异性钙结合蛋白和其他视网膜抗原的异常表达产生免疫反应。结果，光感受器细胞退化。为了阐明复苏素异常表达的病理作用，我们研究了复苏素在多种恶性肿瘤中的表达水平以及复苏素表达对抗癌药物敏感性的影响。方法：采用抗人Recoverin单抗免疫组织化学方法，检测肺癌、胃癌、结肠癌等多种肿瘤组织中Recoverin的表达水平。在多种抗癌药物，包括抗肿瘤抗生素、植物生物碱和抗代谢产物的存在下，以人肺腺癌A549细胞为研究对象，进行细胞毒实验。结果：免疫荧光标记显示，大约10-40%的恶性肿瘤组织中检测到恢复素免疫反应。在恢复素阳性的A549细胞中，抗癌药物的细胞毒作用比恢复素阴性的细胞更高。结论：本研究结果可能与先前的观察结果相一致，即肿瘤细胞可诱导肿瘤免疫，CAR患者的原发肿瘤预后良好。版权所有(C)2009 S.Karger AG，巴塞尔
Purpose: Cancer-associated retinopathy ( CAR) is an ocular manifestation of a paraneoplastic syndrome whereby immunological reactions toward recoverin, a retina-specific calcium binding protein, and other retinal antigens aberrantly expressed in tumor cells are elicited. As a consequence, photoreceptor cell degeneration is induced. To elucidate the pathological role of the aberrantly expressed recoverin, we studied the recoverin expression levels in various malignant tumors and the effects of the expressed recoverin on the sensitivity to anti-cancer drugs. Methods: Recoverin expression levels were determined by immunohistochemistry with anti-human recoverin monoclonal antibody on multiple tissue arrays obtained from several lung, stomach, colon and other cancers. In the presence of several anti-cancer drugs, including anti-tumor antibiotics, plant alkaloids and anti-metabolites, cytotoxicity assay was performed using recoverin-positive or recoverin-negative A549 cells originating from human lung adenocarcinoma. Results: Immunofluorescence labeling revealed that recoverin immunoreactivities were detected at approximately 10-40% of malignant tumor tissues. Cytotoxic effects by anti-cancer drugs were higher in recoverin-positive A549 cells as compared to recoverin-negative cells. Conclusion: The present data may correlate with the previous observation that recoverin-expressing cancer cells induced tumor immunity and a favorable prognosis for primary cancer in CAR patients. Copyright (C) 2009 S. Karger AG, Basel